FDA Statistics Are In

Article

1999 Application and Approval Numbers

Rockville, MD-More new drugs have been approved by the Food and Drug Administration (FDA) for the U.S. market in a shorter time period than in the past. The FDA approved 83 drug applications with a median approval time of 12.0 months in 1999. This is compared to a median approval time of 12.0 months in 1998, 14.4 months in 1997 and 15.4 months in 1996. Twenty-eight of the approvals in 1999 were for priority drugs that were approved in a median time of 6.1 months. The priority and regular approvals in 1999 included 35 new molecular entities that were approved in a median time of 11.6 months compared to a median 12.0 months in 1998 and 13.4 months in 1997.

Twenty-four user fee and non-user fee product license applications were approved in a median time of 8.37 months in 1999. Three approvals were categorized as priority and were approved in a median time of 13.8 months. A total of thirty-nine new product license applications were received for review in 1999, 10 more than were received in 1998.

Forty-one premarket approval applications were approved in the median time of 9.1 months in 1999.

Newsletter

Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.

Recent Videos
 Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
 Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
In a recent discussion with Infection Control Today® (ICT®), study authors Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio, shared their insights on how the project evolved and what the findings mean for the future.